Jonas Persson

Jonas Persson

Affiliated to Research | Docent
Visiting address: Entrévägen 2, 18257 Danderyd
Postal address: D1 Kliniska vetenskaper, Danderyds sjukhus, D1 Kardiologi Kranskärlssjukdom, 171 77 Stockholm
Part of:

About me

  • Please use mail jonas.persson@regionstockholm.se

    I am specialist of Internal Medicine and Cardiology. I hold postions as Senior Consultant in Invasive Cardiology at Danderyd University Hospital, Stockholm, Sweden and as Senior Clinical Researcher, funded by Stockholm County. My major research interests are i) invasive diagnostics and treatment for coronary artery disease and ii) coronary microcirculatory dysfunction and myocardial injury in sepsis. 

Articles

All other publications

Grants

  • Swedish Heart-Lung Foundation
    1 January 2024 - 31 December 2026
    Background We and others have shown that coronary microcirculatory dysfunction (CMVD) with high resting flow is associated with mortality and heart failure. Aim The hypotheses are that coronary microcirculatory dysfunction is i) secondary to angiopoetin-2 downregulation of thrombomodulin ii) involved in early development of heart failure iii) in the acute development of myocardial injury in sepsis Working plan We utilize an invasive method, thermo-dilution, during coronary angiography to diagnose CMVD. CCS We have recruited a CCS-cohort (n=506) with invasive measures of coronary microcirculatory function, a biobank between 2015 and 2022 (HLF grant 20200758). We will do three new analyses in this unique cohort. Study 1. Analysis of thrombomodulin/angiopoetin-2 complexes in plasma to determine if angiopoetin-2 downregulation of thrombomodulin is associated with CMVD in CCS. Study 2. Analysis of pulse wave velocity from aortic pressure waves to determine the relationship between large artery stiffening and the basal and hyperaemic resistance in the LAD of subjects with CCS. Study 3. Analysis the relationship between CMVD and delta_NT-proBNP/year between inclusion and follow-up. Associations between measures of CMVD and higher delta_NT-proBNP/year will indicate that CMVD is predictive of the development of later CHF in CCS patients without known CHF. Sepsis Study 4. We are recruiting sepsis patients (n=54) with non-normal high-sensitive cardiac troponin T (hs-cTnT
    >15 ng/L) in an observational study with invasive measures of coronary microcirculatory function, echocardiography and a biobank. We will investigate if CMVD is involved in myocardial injury in sepsis. Study 5. Analysis of years of lives lost due to myocardial injury and degree of myocardial injury in sepsis. Retrospective cohort study of a large cohort of patients with sepsis in Stockholm (n 3000). Significance Association of CMVD with yearly change in NT-proBNP will confirm involvement of CMVD in the development in CHF and measures of CMVD can be used to identify patients susceptible for CHF. Mechanisms behind glycocalyx shredding in CMVD from experimental models needs to be confirmed in humans. The extent of excess death of myocardial injury in sepsis in relation to comorbidities is not known and needs to be determined. To invasively assess both the coronary macro-and microvascular function is essential to identify mechanisms behind myocardial injury.
  • Swedish Heart-Lung Foundation
    1 January 2020 - 31 December 2020

Employments

  • Affiliated to Research, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2025-2028
  • Affiliated to Research, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2025-2028

Degrees and Education

  • Docent, Cardiology, Karolinska Institutet, 2025
  • Degree Of Doctor Of Philosophy, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2013

News from KI

Events from KI